

## 5-Minute Journal Club: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays in the Treatment of Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements accurately describes outcomes reported by circulating tumor DNA (ctDNA) expression level in an exploratory study for patients with lung cancer?**
  - a. ctDNA positivity correlated with statistically negative recurrence-free survival (RFS) and overall survival (OS) in the preoperative setting
  - b. ctDNA positivity correlated with statistically negative RFS and OS in the postoperative setting**
  - c. Both a and b
  - d. Neither a nor b
- 2. Which of the following conclusions best reflects outcomes reported by ctDNA expression level in the surveillance setting in an exploratory study for patients with resected lung cancer?**
  - a. Persistent ctDNA negativity during the follow-up period after surgery guarantees the disease will not recur radiographically
  - b. Patients with positive ctDNA test results during the follow-up period after surgery tend to experience recurrence and have worse survival outcomes**
  - c. Both a and b
  - d. Neither a nor b
- 3. Which of the following observations best characterizes the correlation between ctDNA clearance and pathologic complete response (pCR) in the Phase III CheckMate 816 study evaluating neoadjuvant nivolumab and chemotherapy versus chemotherapy alone for resectable non-small cell lung cancer (NSCLC)?**
  - a. A strong association between ctDNA clearance and pCR among patients who received chemotherapy alone
  - b. A strong association between ctDNA clearance and pCR among patients who received nivolumab/chemotherapy**
  - c. A strong association between ctDNA clearance and pCR, regardless of the treatment received
- 4. In the Phase III AEGEAN study evaluating perioperative durvalumab and chemotherapy versus chemotherapy alone for resectable NSCLC, what proportion of patients with MRD-positive test results had experienced disease recurrence or died 12 months after surgery?**
  - a. 35%
  - b. 50%
  - c. 76%**
  - d. 100%